Compare ACCO & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACCO | TECX |
|---|---|---|
| Founded | 1893 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.1M | 359.0M |
| IPO Year | N/A | 2018 |
| Metric | ACCO | TECX |
|---|---|---|
| Price | $3.79 | $21.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $81.20 |
| AVG Volume (30 Days) | ★ 793.0K | 306.7K |
| Earning Date | 02-19-2026 | 11-06-2025 |
| Dividend Yield | ★ 7.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,544,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.83 | N/A |
| P/E Ratio | $8.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.20 | $13.70 |
| 52 Week High | $5.68 | $61.07 |
| Indicator | ACCO | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 57.39 |
| Support Level | $3.63 | $18.99 |
| Resistance Level | $3.78 | $21.45 |
| Average True Range (ATR) | 0.08 | 1.19 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 62.96 | 86.94 |
ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.